Somerset, NJ – April 17, 2012 — Norman Weichbrodt, Research & Development Strategic Account Manager for Catalent Pharma Solutions will present “Advanced Aseptic Processing using Blow/Fill/Seal Technology” at Pharma Congress 2012 in Dusseldorf, Germany on Tuesday, April 24, 2012.
In addition to an overview of the blow/fill/seal (BFS) technology, Mr. Weichbrodt will discuss current applications and the flexibility of BFS over other aseptic filling methods. He will also present a case study demonstrating the microbial performance of BFS and, when compared to more traditional methods of aseptic filling, suggest advantages to the process that may ensure the highest quality standards, reduce regulatory risks and enhance product performance and safety.
As well as a broad range of development and manufacturing services, Catalent provides customizable, specialty fill-finish solutions including BFS technology. Because of its unrivalled industry expertise, the company is able to provide customized manufacturing options for the most complex treatments, including emulsions and suspensions, ensuring a reliable global supply with an uncompromising commitment to quality.
Norman Weichbrodt has been with Catalent for more than ten years, and has 30+ years’ experience within the pharmaceutical industry. He is experienced in all phases of aseptic processing including formulation, sterile filling, lyophilization and secondary packaging. During his career he has served in a variety of senior manufacturing and technical roles. He currently works in the New Product Development Group at Catalent’s BFS facility in Woodstock, Illinois, managing technical transfers and product development for strategic customers.
Pharma Congress 2012 takes place in the Swissôtel Congress Center in Dusseldorf, Germany, on 24th and 25th April 2012 and incorporates five international conferences. Mr. Weichbrodt’s presentation will be made during “ECA Conference on Current Aseptic Technologies” at 16:45 on the first day of the conference. For more information on Pharma Congress 2012, visit www.pharma-kongress.com.
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™